TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04308889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cantharone
Description: Cantharone is a clinical blistering agent for topical use to remove warts and molluscum contagiosum. We plan to use the drug to elicit a small skin blister and inflammatory response. This is a well described clinical inflammation research experimental model with multiple publications of its safety and utility in tracking the host inflammatory response.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cantharone
Description: Cantharone is a clinical blistering agent for topical use to remove warts and molluscum contagiosum. We plan to use the drug to elicit a small skin blister and inflammatory response. This is a well described clinical inflammation research experimental model with multiple publications of its safety and utility in tracking the host inflammatory response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Subjects will have blood drawn from the antecubital vein for not more than 15mL at each visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotomy
Description: Subjects will have blood drawn from the antecubital vein for not more than 15mL at each visit.
Study: NCT03237091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unihemispheric transcranial pulsed current stimulation (tPCS)
Description: One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bihemispheric transcranial direct current stimulation (tDCS)
Description: Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
Study: NCT03875170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility. The subject will be asked to perform an isometric contraction, with a series of 3 seconds for sustained contraction and a rest between contraction of 2 to 3 seconds after activating the Golgi apparatus, making an inhibition of the stimulus and bringing the joint and muscle to the highest possible range of motion without pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The active stretching technique will be performed for the hip, quadriceps and hamstring flexors with a voluntary antagonist activation to relax the agonist muscle, holding the movement to be performed for 30 seconds to stimulate the neuromuscular spindle and produce a relaxation of the muscle fibers.
Study: NCT04161638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma Video Exposure
Description: The participants watched a 10 minute video on a computer screen that consisted of brief clips from popular television shows that depicted women with overweight and obesity and evoked negative weight-based stereotypes (e.g., clumsy, loud, and lazy). Both the high blood pressure and normal blood pressure arms participated in this intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma Video Exposure
Description: The participants watched a 10 minute video on a computer screen that consisted of brief clips from popular television shows that depicted women with overweight and obesity and evoked negative weight-based stereotypes (e.g., clumsy, loud, and lazy). Both the high blood pressure and normal blood pressure arms participated in this intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral video exposure
Description: The participants watched a 10 minute video on a computer screen that consisted of a series of clips depicting neutral scenes (e.g., insurance commercials). Both the high blood pressure and normal blood pressure arms participated in this intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral video exposure
Description: The participants watched a 10 minute video on a computer screen that consisted of a series of clips depicting neutral scenes (e.g., insurance commercials). Both the high blood pressure and normal blood pressure arms participated in this intervention.
Study: NCT05076721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: The participants in the simulation group will receive simulation training with high-fidelity manikin to practice and implement one-hour bundle sepsis
Study: NCT04203173

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Patients randomized to the active comparator group will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. BG and BP will be measured daily and results will be uploaded to a secure server. A nurse educator will review the glucose and BP readings and use them to tailor and reinforce behavior change during weekly telephone-delivered diabetes education and skills training session.
Study: NCT00840463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambrisentan
Description: Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study: NCT04622852

Intervention type: DEVICE
Intervention: Open reduction internal fixation (ORIF) with an angular stable plate
Description: Operative treatment of proximal humeral fracture

Intervention type: DEVICE
Intervention: Open reduction internal fixation (ORIF) with an angular stable plate
Description: Operative treatment of proximal humeral fracture
Study: NCT03590457

Intervention type: DEVICE
Group type: OTHER
Intervention: Airvo 2; High-Flow nasal cannula system
Description: Noninvasive device used to deliver humidified oxygen at high flow rates up to 60 liters per minute
Study: NCT03237091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unihemispheric transcranial direct current stimulation (tDCS)
Description: One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham-control
Description: Sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply stimulation to the scalp via the sponges for 1-2 minutes. The stimulator will then be turned off.
Study: NCT03506126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leucine
Description: There are 8 different leucine test levels ranging from 20 to 120 mg of leucine per kilogram body weight per day (20-120 mg/kg/d)
Study: NCT01138163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus bavituximab or placebo
Description: Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.
Study: NCT02262611

Intervention type: DRUG
Intervention: MicardisPlus®
Study: NCT02580552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobomarsen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobomarsen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobomarsen
Study: NCT01138163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel plus bavituximab or placebo
Description: Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel plus bavituximab or placebo
Description: Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.
Study: NCT03409302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALGEApp (Brief iACT intervention)
Description: Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The i-ACT intervention participants will be encouraged to login the website platform with their credentials and to complete 4 weekly sessions (1 session per week) which lasts about 1 hour each. Participants will be guided by a 3D- animated Avatar who adopts the role of a facilitator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control group
Description: Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The active control group will have access, through the same platform. only to limited online psycho-educational information regarding pain. Active control group will complete pre-treatment and post-treatment questionnaires in parallel with the intervention group.
Study: NCT02362438

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: scAAv9/JeT-GAN
Description: scAAV9/JeT-GAN is a biological gene transfer reagent

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: scAAv9/JeT-GAN
Description: scAAV9/JeT-GAN is a biological gene transfer reagent

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: scAAv9/JeT-GAN
Description: scAAV9/JeT-GAN is a biological gene transfer reagent

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: scAAv9/JeT-GAN
Description: scAAV9/JeT-GAN is a biological gene transfer reagent
Study: NCT02580552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobomarsen
Study: NCT01649492

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pineapple juice (Carrefour n°1) 500 ml/day 5 days
Study: NCT00934895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abraxane
Description: Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
Study: NCT00605319

Intervention type: DRUG
Group type: OTHER
Intervention: Toviaz (Fesoterodine)
Description: 4mg to 8mg by mouth once daily
Study: NCT01508299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin test
Description: skin test with the Suspected raw food
Study: NCT03414879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: While in the semi-setting position, patients will receive nebulization with ketamine 3 mg/kg to be completed with normal saline solution to reach a volume of 6 ml (K group; n=30) for 15 minutes before commencing the awake fiberoptic intubation..

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: While in the semi-setting position, patients will receive nebulization with lidocaine 4% 6 ml (L group; n=30) for 15 minutes before commencing the awake fiberoptic intubation
Study: NCT03410147

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 13C-octanoate breath test for gastric emptying
Description: The 13C-octanoate breath test for gastric emptying will be performed to assess gastric emptying rate of a liquid meal that is infused continuously over a period of 8 hour.~13C-labeled sodium octanoate (food adjective) is mixed with liquid nutrients used for enteral feeding. The concentration of 13C-labeled sodium octanoate is according to the randomized treatment order. This mixture is infused at 20 ml/h for 8 hours (hourly dose of 13C-octanoate differs between treatment arms). In order to estimate gastric emptying rate quantitatively throughout the infusion period, the appearance of 13CO2 in the breath, relative to 12CO2, will be monitored by sampling the exhaled breath at a 15 minute interval.~The aim is to induce a steady state hourly 13C-recovery. This would allow to implement the prolonged breath test protocol in future clinical investigations.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 13C-octanoate breath test for gastric emptying
Description: The 13C-octanoate breath test for gastric emptying will be performed to assess gastric emptying rate of a liquid meal that is infused continuously over a period of 8 hour.~13C-labeled sodium octanoate (food adjective) is mixed with liquid nutrients used for enteral feeding. The concentration of 13C-labeled sodium octanoate is according to the randomized treatment order. This mixture is infused at 20 ml/h for 8 hours (hourly dose of 13C-octanoate differs between treatment arms). In order to estimate gastric emptying rate quantitatively throughout the infusion period, the appearance of 13CO2 in the breath, relative to 12CO2, will be monitored by sampling the exhaled breath at a 15 minute interval.~The aim is to induce a steady state hourly 13C-recovery. This would allow to implement the prolonged breath test protocol in future clinical investigations.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 13C-octanoate breath test for gastric emptying
Description: The 13C-octanoate breath test for gastric emptying will be performed to assess gastric emptying rate of a liquid meal that is infused continuously over a period of 8 hour.~13C-labeled sodium octanoate (food adjective) is mixed with liquid nutrients used for enteral feeding. The concentration of 13C-labeled sodium octanoate is according to the randomized treatment order. This mixture is infused at 20 ml/h for 8 hours (hourly dose of 13C-octanoate differs between treatment arms). In order to estimate gastric emptying rate quantitatively throughout the infusion period, the appearance of 13CO2 in the breath, relative to 12CO2, will be monitored by sampling the exhaled breath at a 15 minute interval.~The aim is to induce a steady state hourly 13C-recovery. This would allow to implement the prolonged breath test protocol in future clinical investigations.
Study: NCT01195025

Intervention type: DRUG
Group type: OTHER
Intervention: acetated Ringers
Description: Infusion of Ringer acetate 20 ml/kg over 30 min
Study: NCT02580552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobomarsen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobomarsen
Study: NCT01195025

Intervention type: DRUG
Group type: OTHER
Intervention: acetated Ringers
Description: Infusion of Ringer acetate 20 ml/kg over 30 min

Intervention type: DRUG
Group type: OTHER
Intervention: acetated Ringers
Description: Infusion of Ringer acetate 20 ml/kg over 30 min

Intervention type: DRUG
Group type: OTHER
Intervention: acetated Ringers
Description: Infusion of Ringer acetate 20 ml/kg over 30 min

Intervention type: DRUG
Group type: OTHER
Intervention: acetated Ringers
Description: Infusion of Ringer acetate 20 ml/kg over 30 min
Study: NCT04041518

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autotransplantation
Description: Autotransplantation of tooth with an almost fully or completely developed root with intraoperative extraoral apicoectomy.
Study: NCT02663167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioral Therapy
Description: The treatment consists of a standard cognitive behavioral therapy for obsessive-compulsive disorder. The treatment is delivered through an Internet platform. The child and his/her parent(s) work through the treatment with regular therapist contact several times per week.
Study: NCT00745160

Intervention type: OTHER
Intervention: blood sample and questionnaire
Description: After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
Study: NCT01195025

Intervention type: DRUG
Group type: OTHER
Intervention: colloid
Description: Infusion of starch 10 ml/kg over 30 min
Study: NCT04631978

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive ophthalmologic examination
Description: Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive ophthalmologic examination
Description: Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.
Study: NCT01195025

Intervention type: DRUG
Group type: OTHER
Intervention: colloid
Description: Infusion of starch 10 ml/kg over 30 min

Intervention type: DRUG
Group type: OTHER
Intervention: colloid
Description: Infusion of starch 10 ml/kg over 30 min

Intervention type: DRUG
Group type: OTHER
Intervention: colloid
Description: Infusion of starch 10 ml/kg over 30 min

Intervention type: DRUG
Group type: OTHER
Intervention: colloid
Description: Infusion of starch 10 ml/kg over 30 min

Intervention type: DRUG
Group type: OTHER
Intervention: colloid+acetated Ringer
Description: Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.

Intervention type: DRUG
Group type: OTHER
Intervention: colloid+acetated Ringer
Description: Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.

Intervention type: DRUG
Group type: OTHER
Intervention: colloid+acetated Ringer
Description: Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
Study: NCT04354571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: An ultrasound-guided Erector spinae plane block was performed with the patient lying on the his side and the surgical side on the top. After skin disinfection, sterile draping was be placed and the ultrasound probe was sheathed. The level of the block was the transverse process of L2. The block was performed using a 9-12 MHz linear probe (LOGIQe, GE Healthcare, USA), which was placed in a parasagittal plane 1 cm from the posterior midline. The deep plane to the erector spinae muscle (ESM) was identified, and a 22 G, 50 mm insulated needle (Sonoplex Stim, Pajunk, Germany) was inserted cranio-caudally in plane between the transverse process and the fascia of the ESM. After negative aspiration, 0.3 ml/kg of 0.25% bupivacaine was injected to confirm the correct position by visualizing the solution lifting the ESM off the transverse process.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: caudal block was performed using anatomical landmarks and ultrasound guided and confirmed with a concentration of bupivacaine of 0.25%.
Study: NCT02606539

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total abdominal hysterectomy and methotrexate
Description: After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate plus folinic acid alone
Description: methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG